Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIAN-SHAN8: DZD6008 plus sunvozertinib in EGFR-mutant advanced or metastatic non-small cell lung cancer
CTR20252605Phase 2Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DZD6008, sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jul 2025; status: active.
02
Drugs
DZD6008sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252605.